I appreciate that people not close to the science could view the drug development of these RNA drugs very risky.
Maybe we should just wind back to focus on the first drug RP 11 for the eye.
this drug is already in human trials and the results most encouraging … annual market value of the drug ~$1 billion and it could be approved as early as 2028
the drug is monogenic, already tested on human tissue, no adverse side effects to date and the volume of drug into the eye ball of these going blind people is minuscule
discounted cashflow of that would yield handsome reward to holders
I appreciate that people not close to the science could view the...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.020(1.77%) |
Mkt cap ! $670.7M | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.18 | $1.11 | $172.3K | 151.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 592 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 4211 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |